Frontier IP Advances ASF Vaccine Development

Frontier IP (GB:FIPP) has released an update.

Frontier IP Group plc’s portfolio company, The Vaccine Group, is partnering with The Pirbright Institute to develop a vaccine against African swine fever, a disease threatening global pig populations and food security. The UK’s pig and pork export market stands to benefit from the collaboration, as it is valued at £623 million. The project, supported by UK government funding, will use innovative herpesvirus-based technology in hopes of creating an effective vaccine.

For further insights into GB:FIPP stock, check out TipRanks’ Stock Analysis page.